Market Cap (In USD)
157.12 Million
Revenue (In USD)
13.59 Million
Net Income (In USD)
-54.81 Million
Avg. Volume
267.24 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 3.075-6.71
- PE
- -
- EPS
- -
- Beta Value
- 0.14
- ISIN
- US8106481059
- CUSIP
- 810648105
- CIK
- 1604950
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. John H. Tucker
- Employee Count
- -
- Website
- https://www.scpharmaceuticals.com
- Ipo Date
- 2017-11-17
- Details
- scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
More Stocks
-
PCPDF
-
HRBH&R Block, Inc.
HRB
-
347850D&D Pharmatech
347850
-
RMC
-
SARDAENSarda Energy & Minerals Limited
SARDAEN
-
000521Changhong Meiling Co., Ltd.
000521
-
CWV
-
PREKFPrairieSky Royalty Ltd.
PREKF